C9ORF72 Amyotrophic Lateral Sclerosis (ALS)

Neurology
0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Biogen
BiogenCAMBRIDGE, MA
1 program
Understanding Clinical Phenotype and Collecting Biomarker Samples in C9ORF72 ALSN/A1 trial
Active Trials
NCT02686268Completed128Est. Oct 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
BiogenUnderstanding Clinical Phenotype and Collecting Biomarker Samples in C9ORF72 ALS

Clinical Trials (1)

Total enrollment: 128 patients across 1 trials

NCT02686268BiogenUnderstanding Clinical Phenotype and Collecting Biomarker Samples in C9ORF72 ALS

Understanding Clinical Phenotype and Collecting Biomarker Samples in C9ORF72 ALS

Start: Feb 2015Est. completion: Oct 2018128 patients
N/ACompleted

Related Jobs in Neurology

Director, Distribution & Services

Xenon Pharmaceuticals
Remote
10h ago

Senior Medical Science Liaison (NYC Tri-State)

Xenon Pharmaceuticals
Remote
10h ago
$208K - $234K/yr

Director of Medical Affairs

CoMind
Miami, FL
10h ago

Director of Finance

CoMind
London, UK
10h ago

Electronics Engineering Manager

CoMind
London, UK
10h ago

Director of Information Technology

Zavation Medical Products
10h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space

Related Indications

Multiple Sclerosis(274)Schizophrenia(255)Epilepsy(242)Parkinson Disease(171)Alzheimer's Disease(165)Parkinson's Disease(160)Alzheimer Disease(117)Stroke(102)Relapsing-Remitting Multiple Sclerosis(83)Depression(82)